Hosted on MSN1y
China NMPA grants IND clearance for Fermion’s TYK2 JH2 inhibitor
The China National Medical Products Administration (NMPA) has granted clearance for the investigational new drug (IND) application of Guangzhou Fermion Technology’s FZ007-119. This is the ...
Hosted on MSN2mon
This Wild Quasiparticle Switches Between Having Mass and Being Massless. It All Depends on the Direction It Travels
This peculiar particle, called a semi-Dirac fermion, was first predicted 16 years ago. Now, it’s been spotted inside a semi-metal crystal of zirconium silicon sulfide (ZrSiS). The discovery ...
AdnKronos23d
Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain
GUANGZHOU, China, Jan. 18, 2025 /PRNewswire/ -- Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical ...
Scientific American28d
Exotic ‘Paraparticles’ That Defy Categorization May Exist in Many Dimensions
In a separate development published late last year in Science, physicists experimentally demonstrated another kind of particle that is neither a boson nor a fermion — an ‘anyon’ — in a ...
BBC4y
The Standard Model Bosons
Bosons are the 'force carrying' or 'force-mediating' particles. If a fermion, such as a quark or lepton produces a boson, which is then taken in by another fermion, then a force exists between the ...
Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain
Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.